RU2239436C1 - Agent for treatment of dry eye syndrome as complication after ophthalmic infection - Google Patents

Abstract

FIELD: medicine, ophthalmology.

SUBSTANCE: invention relates to treatment of dry eye syndrome after ophthalmic infections and for treatment of dry eye syndrome of other etiology also. Agent for treatment comprises polyglucin and autoserum from patient taken in the ratio 1:1, and carnosine as an antioxidant in the concentration 0.2%, not above. Agent provides forming the stable precorneal lachrymal film and achievement of compensation of pathological process.

EFFECT: valuable medicinal properties of agent.

2 ex

Description

The invention relates to ophthalmology and can be used to treat dry eye syndrome (CVH) in patients who have experienced viral diseases of the anterior segment of the eye. The algorithm for the treatment of ophthalmic infections has been sufficiently developed and the relief of the acute process is achieved in the shortest possible time. However, after some time, patients have complaints of discomfort, redness of the eyes, burning, itching, etc. When a doctor visits the ophthalmologist again, this condition is most often assessed as a relapse of a viral disease and appropriate therapy is prescribed. The use of potent drugs leads to a deterioration and aggravation of the process. The reason for repeated requests for ophthalmic care is most often a violation of tear production after an acute viral process.

Various methods for the treatment of CVD are known, based on the use of artificial tear preparations, often in combination with other drugs. The goal of tear replacement therapy is to create a stable precorneal lacrimal film providing mechanical, immune tissue protection and nutrition of the anterior segment of the eye. The disadvantages of these methods of treatment are the individual intolerance of artificial tear preparations, the occurrence of toxic-allergic reactions, the development of addiction and low efficiency. In addition, tear replacement drugs are universal remedies that are not adapted to a particular patient.

An analogue of the invention is the drug polyglucin. Polyglukin is a solution of the molecular weight fraction of partially hydrolyzed dextran in an isotonic sodium chloride solution. Being a plasma-replacing drug, polyglucin is as close as possible to the molecular weight of blood albumin, it circulates for a long time in the bloodstream. By relative viscosity and pH, polyglucin is close in composition to a tear, which makes it possible to use it as a preparation of artificial tears. (A manual for doctors “Methods for the diagnosis of dry eye syndrome in patients who underwent adenoviral ophthalmic infection." M., 2002) The drug is prescribed in installations 6-12 times a day. The disadvantage of this drug is individual intolerance, the occurrence of toxic-allergic reactions, the formation of an insufficiently stable tear film, a long-term therapeutic effect is not always ensured.

The closest analogue is polyglucin in combination with taufon. Taufon helps to improve energy processes, stimulates reparative processes, and is used as an antioxidant. The drug is prescribed 4-6 times a day. The disadvantages of the drug are the same as polyglucin, individual taufon intolerance is possible. (A manual for doctors “Methods for the diagnosis of dry eye syndrome in patients undergoing adenoviral ophthalmic infection." M., 2002.)

The objective of the invention is to create a medicinal product for the treatment of CVD after undergoing ophthalmic infections. Conducting a course of treatment using this agent allows the formation of a stable precorneal lacrimal film, which prevents the further development of the disorder and helps to restore tear production.

The technical result of the proposed drug is to form a stable precorneal lacrimal film and prevent the development of CVH after undergoing ophthalmic infections. The technical result is achieved through the use of autoserum of the patient as a drug that is as close as possible in its biochemical composition to the composition of the tears of a particular patient. The presence of carnosine in a certain concentration allows you to accelerate the metabolic processes in the tissues of the conjunctiva. Carnosine is also used as an antioxidant.

To implement the method using the inventive means, venous blood is collected from a patient, centrifuged at a speed of 1000 rpm. The exfoliated serum is pumped into a sterile vial, polyglucin is added in a ratio of 1: 1 and carnosine as an antioxidant and stabilizer in a percentage concentration of not more than 0.2%.

Polyglukin provides a sufficient viscosity of the drug, its pH. Autoserum optimally approximates the biochemical composition of the drug to the composition of the patient's own tear.

Carnosine is used as an antioxidant, stabilizer, and also accelerates the energy processes in the tissues of the conjunctiva and cornea.

The ratio of drugs is the optimal combination that ensures the formation of a stable, full-fledged precorneal lacrimal film, good drug tolerance, long-term therapeutic effect and the possibility of preventing CVH after eye infections.

The drug is used in installations 6-12 times a day. If necessary, reparative and anti-allergic drugs are added to the treatment.

The proposed tool was received by 36 patients aged 24 to 68 years, 26 women, 10 men. The observation period is from 1 to 12 months.

Example 1

Patient N., born in 1952.

In 1998, she suffered adenoviral conjunctivitis. In the acute period, standard therapy was carried out: interferon, spersallerg, albucid, antihistamines inside. In the course of treatment, positive dynamics were noted and after 2 weeks the patient was healthy. A month later, the patient had a sensation of clogged eyes, periodic redness, burning, rapid fatigue. With repeated treatment, a violation of tear production and the development of dry conjunctivitis were diagnosed. In the process of treatment, the whole range of artificial tear preparations was used, both domestic and imported. Unstable positive dynamics was noted, followed by an allergic reaction from the conjunctiva and the need to replace the drug. The use of autoserum with carnosine in this case made it possible to achieve persistent (within a few months after treatment) compensation of the pathological process. It can be noted that the drug is well tolerated - the absence of allergic reactions during treatment and the improvement of subjective sensations. It was possible to achieve stabilization of the process and prevent the inclusion of the cornea in the pathological process.

Example 2

Patient X., born in 1932.

First contacted the Research Institute of GB them. Helmholtz in 2000 with a diagnosis of OS - herpetic keratitis. The course of standard therapy - zovirax ointment, vitasic, albucid, desensitizing drugs inside - helped to compensate for the acute process and the formation of slight corneal opacity. However, the corneal epithelium was periodically desquamated, forming zones of staining with fluorescein, and point epithelialopathy arose, accompanied by corresponding complaints. After a diagnostic study, he was diagnosed with OS - dry keratoconjunctivitis. Attempts to select tear replacement therapy did not give positive clinical dynamics - point epithelialopathy persisted. It should also be noted the poor tolerance of the patient’s drugs - a burning sensation, eye contraction, redness, itching within 15-30 minutes after instillation.

An attempt to instill autoserum with carnosine in this patient allowed us to improve the condition of the cornea and achieve a compensation process. The drug was well tolerated, there were no sensations of discomfort after instillation. Thus, the proposed drug, including polyglucin and an antioxidant (carnosine), characterized in that it, additionally containing the patient’s autoserum, allows for the creation of a stable precorneal lacrimal film that provides full mechanical protection, has a reparative effect and has good tolerance. The tool can be used both for the prevention of dry eye syndrome after undergoing ophthalmic infections, and for the treatment of other varieties of CVD - C. Sjögren, systemic pathology and other diseases accompanied by lesions of the cornea, including after undergoing refractive surgeries, in particular Lasic.

Claims (1)

An agent for treating dry eye syndrome as a complication of an ophthalmic infection, including polyglucin and an antioxidant, characterized in that it additionally contains autoserum, while the ratio of polyglucin and autoserum is 1: 1, and the content of caronosin antioxidant is not more than 0.2%.